Cancer patients with heavy tumor mutational burden, abundant pre-treatment tumor-infiltrating T cells, and elevated pre-treatment PD-L1 levels on tumor cells are expected to respond more favorably to anti-PD-1/PD-L1 immunotherapy[93]. The gene discussed is CD274; the disease is cancer.